Molecular data
| Molecular formula | C187H291N45O59 |
|---|---|
| Molecular weight | 4113.58 Da |
| Sequence | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-gGlu-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Sequence length | 31 residues |
| CAS / identifier | 910463-68-2 |
| Physical form | Lyophilized powder |
| Available sizes | 20mg |
How it works
-
GLP-1R
GLP-1 Receptor Agonism
Selectively binds GLP-1 receptors. Published characterisation describes glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying in study models. Insulin response scales with glucose, a property examined relative to non-incretin secretagogues.
- Glucose-dependent insulin secretion
- Glucagon suppression
- Delayed gastric emptying
-
CNS
Central GLP-1R Signalling
Engages GLP-1 receptors in the hypothalamus and hindbrain, with hunger, satiety and energy intake as the measured endpoints.
- Food intake measured
- Satiety signalling measured
- Lower caloric intake
-
PK
Extended Half-Life Design
A C18 fatty-diacid chain confers reversible albumin binding and resistance to DPP-4 degradation, extending the plasma half-life to roughly 7 days in research models.
- ~165-hour half-life
- Albumin-binding modification
- DPP-4 resistant
What the research shows
-
Metabolic
Metabolic Receptor Research
GLP-1 receptor agonism is a principal focus of metabolic research, and GLP-1 S is a selective agonist used as a reference compound in that work.
-
Endocrine
Glycemic Pathway Research
GLP-1 S is studied for glucose-dependent insulin secretion and glycemic endpoints in metabolic research.
-
Cardiometabolic
Cardiovascular Outcomes
Cardiometabolic signalling is a further area of research interest for this receptor class, beyond glucose handling.
-
Neuroscience
Hypothalamic & Reward Circuitry
GLP-1 receptor signaling in the hypothalamus and hindbrain modulates satiety and food-reward pathways, a focus of ongoing neuroscience research.
Specification
| Compound Class | GLP-1 receptor agonist (incretin mimetic) |
|---|---|
| Research Name | GLP-1 S |
| Target | GLP-1 receptor (GLP-1R) |
| Form | Lyophilized powder |
| Molecular Weight | 4,113.58 g/mol |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Half-Life | ~165 hours (~7 days) |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
How it's tested
Every lot of GLP-1 S released to the catalog carries a third-party certificate of analysis. 1 documented lot is on file for this compound, with reported HPLC purity from 99.77% to 99.77% (mean 99.77%), issued by Accurate Test Labs. 1 of 1 certificates record identity as confirmed.
- Documented lots
- 1
- Reported purity
- 99.77% to 99.77%
- Mean purity
- 99.77%
- Issuing labs
- Accurate Test Labs
- 2026-08-18 Lot UJ68ETAccurate Test Labs 99.77% View certificate
Frequently asked questions
What is GLP-1 S?
GLP-1 S is a long-acting and selective GLP-1 receptor agonist. It mimics the incretin hormone GLP-1; published characterisation describes glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and central appetite-pathway signalling.
How does it differ from GLP-2 TZ and GLP-3 RT?
GLP-1 S is a single-receptor (GLP-1) agonist. GLP-2 TZ is a dual GLP-1/GIP agonist, and GLP-3 RT is a triple GLP-1/GIP/glucagon agonist. The distinction is receptor coverage.
What is the molecular weight and purity?
GLP-1 S has a molecular weight of 4,113.58 g/mol. Every vial is supplied at ≥99% purity, verified by HPLC, with a Certificate of Analysis included.
How should it be stored?
Store lyophilized vials at -20°C for long-term stability, protected from light and moisture.
Is this product for human use?
No. GLP-1 S is sold strictly as a research compound for laboratory and in-vitro use only. It is not intended for human or animal consumption, diagnosis, or treatment.
Related monographs
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.